STOCK TITAN

Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Streamline Health Solutions (Nasdaq: STRM) reported fourth quarter revenues of $6.0 million, a 100% increase year-over-year, with SaaS revenue growth of 155%. For the full fiscal year 2021, revenues reached $17.4 million, up 54% from $11.3 million in 2020. The net loss for Q4 was ($30,000), improving from ($1.2 million) in Q4 2020. Adjusted EBITDA was ($0.3 million). Pro forma revenue for FY 2021 was approximately $22.6 million, with SaaS contributing $11.3 million, an 82% increase. Management anticipates continued growth following operational impacts from the pandemic.

Positive
  • Fourth quarter revenue of $6.0 million, a 100% increase year-over-year.
  • SaaS revenue for Q4 grew by 155% compared to Q4 2020.
  • Total FY 2021 revenue increased by 54% to $17.4 million.
  • Pro forma revenue for FY 2021 was approximately $22.6 million, a 15% increase.
  • SaaS revenue for FY 2021 reached $11.3 million, up 82% from FY 2020.
Negative
  • Net loss of $30,000 in Q4 2021, despite improvements from a previous loss of $1.2 million.
  • Full year net loss of ($6.5 million) in 2021, down from net income of $0.3 million in 2020.
  • Adjusted EBITDA loss for Q4 was ($0.3 million), worsening slightly from ($0.1 million) in Q4 2020.

Fourth Quarter Revenues of $6.0 Million; 155% SaaS Revenue Growth; $30,000 in Net Loss; ($0.3) Million in Adjusted EBITDA

Atlanta, GA, April 27, 2022 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fourth quarter and fiscal year 2021, which ended January 31, 2022.

Fiscal Fourth Quarter and Full Year 2021 Financial Results

The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (GAAP). Fiscal fourth quarter 2021 financial results represent the consolidation of the Company with Avelead Consulting, LLC (“Avelead”), which was acquired in the fiscal third quarter 2021. Fiscal fourth quarter and full year 2020 (GAAP) financial results do not reflect results from Avelead’s operations.

Total revenues for the fourth quarter of fiscal 2021 were $6.0 million, a 100% increase from $3.0 million during the fourth quarter of fiscal 2020. Fiscal year 2021 revenues were $17.4 million, a 54% increase compared to $11.3 million during the fiscal year 2020. The increase in revenue for the quarter and year was the result of higher revenue from SaaS and professional services primarily as a result of the Avelead acquisition. Recurring revenue comprised 64% and 71% of total revenue for the three- and twelve-month periods ended January 31, 2022, respectively, as compared to 70% and 73% for the comparable prior year periods.

The Company is focused on the growth of its SaaS solutions. During the fourth quarter of 2021, SaaS revenue grew $1.7 million or 155% compared to the fourth quarter of 2020 and $4.4 million or 119% during the fiscal year ended January 31, 2022, compared to the prior fiscal year.

Net loss for the fourth quarter of fiscal 2021 was ($30,000) as compared to a net loss of ($1.2) million during the fourth quarter of fiscal 2020. Net loss for the fourth quarater of fiscal 2021 included $0.1 million of non-routine costs and other income of $2.3 million dollars primarily related to a valuation adjustment arising from the acquisition of Avelead. The Company’s net loss in the fourth quarter of 2021 was also impacted by higher operating cost and amortization cost from the Avelead acquisition.

Net loss for fiscal 2021 was ($6.5) million, as compared to net income of $0.3 million for 2020. Net loss for fiscal 2021 included $2.9 million dollars of non-routine costs and other income of $1.9 million dollars; each are primarily related to the acquisition of Avelead. The Company’s net loss in fiscal 2021 was also impacted by higher operating cost and amortization cost from the Avelead acquisition.

Adjusted EBITDA for the fourth quarter of fiscal 2021 was a loss of ($0.3) million, compared to an adjusted EBITDA loss of ($0.1) million in the fourth quarter of fiscal 2020. Adjusted EBITDA for the fiscal year ended January 31, 2022, was a loss of ($2.0) million as compared to an adjusted EBITDA loss of ($1.9) million during fiscal 2020.

Full Year 2021 Financial Results (Pro Forma)

The following financial results are pro forma and have not been prepared in accordance with GAAP. These pro forma financial results represent the consolidation of the Company with Avelead as if Avelead’s operations were fully recognized during both comparable periods.

Pro forma, unaudited, consolidated revenue for the fiscal year 2021 was approximately $22.6 million, a 15% increase compared to approximately $19.7 million in fiscal year 2020. SaaS revenue comprised approximately $11.3 million of this total, up 82% from approximately $6.2 million in fiscal year 2020.

Management Commentary

“Over the last twelve months, we’ve laid a foundation for the future that we believe has positioned our business for high-margin, recurring revenue growth. Between the acquisition of Avelead and the transformation of our eValuator sales and leadership teams, we believe Streamline is in a better position than ever to serve our healthcare partners and help improve their financial performance,” stated Tee Green President and Chief Executive Officer, Streamline Health. “With the operational impacts of the pandemic easing, we are confident that the investments we made in our eValuator salesforce will translate to improved bookings momentum in fiscal 2022. In recent weeks we’ve already announced several new and expanded contracts with major providers across the country, and we expect this activity to accelerate in the coming quarters.”

Highlights from the fourth quarter and fiscal year ended January 31, 2022, included:

  • Revenue for the fourth quarter of fiscal 2021 was $6.0 million;
  • SaaS revenue for the fourth quarter of fiscal 2021 grew 155% compared to the fourth quarter of fiscal 2020;
  • Net loss for the fourth quarter of fiscal 2021 was $30,000;
  • Adjusted EBITDA for the fourth quarter of fiscal 2021 was a loss of $(0.3) million;
  • Total bookings (total contract value) for the fourth quarter of fiscal 2021 were $1.3 million;
  • Appointed Amy Sebero as Chief Growth Officer, eValuator Solutions and promoted Ben Stilwill to President & CEO, eValuator Solutions, strategic improvements designed to accelerate growth;
  • Expanded Avelead leadership team, adding Chief Technology Officer and Senior Vice President of Services.

Conference Call

The Company will conduct a conference call on Thursday, April 28, 2022 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.

A replay of the conference call will be available from Thursday, April 28, 2022, at 12:00 PM ET to Thursday, May 5, 2022 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13724715. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.

Non-GAAP Financial Measures

Streamline reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline's management believes that this measure provides useful supplemental information regarding the performance of Streamline's business operations.

Streamline defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure and reconciling adjusted EBITDA to loss from continuing operations, the most comparable GAAP measure, is included in this press release.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of backlog, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, pro forma financial information, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Company Contact

Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
Jacob.goldberger@streamlinehealth.net

STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
          
  Three Months Ended  Twelve Months Ended
  January 31  January 31
  2022  2021   2022  2021 
Total Revenue $ 6,046,000   $ 2,974,000   $ 17,379,000  $ 11,346,000  
Operating expenses:         
Cost of sales 3,081,000  1,589,000   8,577,000  5,689,000 
Selling, general and administrative expense 3,424,000  1,706,000   11,931,000  8,565,000 
Research and development 1,502,000  987,000   4,782,000  2,933,000 
Non-routine costs 146,000  -   2,856,000  - 
Loss on exit from membership agreement -  -   -  105,000 
Total operating expenses 8,153,000  4,282,000   28,146,000  17,292,000 
Operating loss (2,107,000) (1,308,000)  (10,767,000) (5,946,000)
Other income (expense):         
Interest income (expense) (129,000) (12,000)  (236,000) (51,000)
Loss on Extinguishment of Debt -  -   (43,000) - 
Other 2,332,000  6,000   1,911,000  (62,000)
PPP Loan Forgiveness -  -   2,327,000  - 
Loss from continuing operations before income taxes 96,000  (1,314,000)  (6,808,000) (6,059,000)
Income tax (expense) benefit (100,000) (276,000)  (109,000) 1,260,000 
Loss from continuing operations (4,000) (1,590,000)  (6,917,000) (4,799,000)
Income from discontinued operations:         
Gain on sale of discontinued operations -  -   -  6,013,000 
Income from discontinued operations -  51,000   401,000  356,000 
Income tax (expense) benefit from discontinued operations (26,000) 352,000   (26,000) (1,274,000)
(Loss) Income from discontinued operations, net of tax (26,000) 403,000   375,000  5,095,000 
Net (loss) income$(30,000)$(1,187,000) $(6,542,000)$296,000 
          
Basic Earnings Per Share:         
Continuing operations$- $(0.05) $(0.16)$(0.16)
Discontinued operations -  0.01   0.01  0.17 
Net (loss) income$- $(0.04) $(0.15)$0.01 
          
Weighted average number of common shares - basic 46,764,335  30,528,863   42,815,239  30,152,383 
          
Diluted Earnings Per Share:         
Continuing operations$- $(0.05) $(0.16)$(0.16)
Discontinued operations -  0.01   0.01  0.17 
Net income$- $(0.04) $(0.15)$0.01 
          
Weighted average number of common shares - diluted 47,108,495  31,211,252   43,273,574  30,640,742 


STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED AND CONDENSED BALANCE SHEETS

(rounded to the nearest thousand dollars, except share and per share information)

  January 31, 
  2022  2021 
ASSETS        
Current assets:        
Cash and cash equivalents $9,885,000  $2,409,000 
Accounts receivable, net  3,823,000   2,929,000 
Contract receivables  843,000   174,000 
Assets held in escrow     800,000 
Prepaid and other current assets  568,000   416,000 
Current assets of discontinued operations     587,000 
Total current assets  15,119,000   7,315,000 
Non-current assets:        
Property and equipment, net of accumulated amortization  123,000   104,000 
Right-of use asset for operating lease  218,000   391,000 
Capitalized software development costs, net  5,555,000   5,945,000 
Intangible assets, net  16,763,000   624,000 
Goodwill  23,089,000   10,712,000 
Other  948,000   873,000 
Long-term assets of discontinued operations     13,000 
Total non-current assets  46,696,000   18,662,000 
Total assets $61,815,000  $25,977,000 


  January 31,
  2022  2021
LIABILITIES AND STOCKHOLDERS’ EQUITY       
Current liabilities:       
Accounts payable $778,000  $272,000
Accrued expenses  1,803,000   908,000
Current portion of term loan, net of deferred financing costs  250,000   1,534,000
Deferred revenues  5,794,000   3,862,000
Current portion of operating lease obligation  204,000   198,000
Current portion of acquisition earnout liability  4,672,000   
Current liabilities of discontinued operations     595,000
Total current liabilities  13,501,000   7,369,000
Non-current liabilities:       
Term loan, net of current portion and deferred financing costs  9,654,000   767,000
Deferred revenues, less current portion  136,000   130,000
Operating lease obligations, less current portion  33,000   222,000
Acquisition earnout liability, less current portion  4,161,000   
Other non-current liabilities  286,000   
Total non-current liabilities  14,270,000   1,119,000
Total liabilities  27,771,000   8,488,000
Stockholders’ equity:       
Common stock  478,000   316,000
Additional paid in capital  119,225,000   96,290,000
Accumulated deficit  (85,659,000)  (79,117,000
Total stockholders’ equity  34,044,000   17,489,000
Total liabilities and stockholders’ equity $61,815,000  $25,977,000


STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(rounded to the nearest thousand dollars, except share information)

  Fiscal Year
  2021 2020
Cash flows from operating activities:        
Net (loss) income $(6,542,000) $296,000 
LESS: Income from discontinued operations, net of tax  375,000   5,095,000 
Loss from continuing operations, net of tax  (6,917,000)  (4,799,000)
         
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation  68,000   64,000 
Amortization of capitalized software development costs  1,848,000   1,662,000 
Amortization of intangible assets  1,281,000   491,000 
Amortization of other deferred costs  449,000   359,000 
Amortization of Deferred Financing Costs  51,000   —  
Valuation adjustments  (1,851,000)  31,000 
Loss on early extinguishment of debt  43,000   —   
Provision (benefit) for income taxes  95,000   (1,274,000)
Loss on exit of operating lease  —     105,000 
Share-based compensation expense  2,216,000   1,403,000 
Provision (benefit) for accounts receivable allowance  11,000   (31,000)
Forgiveness of PPP Loan  (2,327,000)  —   
Changes in assets and liabilities:        
Accounts and contract receivables  (129,000)  (253,000)
Other assets  (346,000)  (519,000)
Accounts payable  17,000   (484,000)
Accrued expenses and other liabilities  533,000   (592,000)
Deferred revenues  1,074,000   344,000 
Net cash used in operating activities – continuing operations  (3,884,000)  (3,493,000)
Net cash provided by (used in) operating activities – discontinued operations  380,000   (2,264,000)
Cash flows from investing activities:        
     Investment in Avelead, net of cash acquired  (12,470,000)  —   
Purchases of property and equipment  (41,000)  (44,000)
Proceeds from sale of ECM assets  800,000   11,288,000 
Capitalization of software development costs  (1,458,000)  (1,784,000)
Net cash (used in) provided by investing activities – continuing operations  (13,169,000)  9,460,000 
         
Cash flows from financing activities:        
Proceeds from issuance of common stock  16,100,000   —   
Payments for costs directly attributable to the issuance of common stock  (1,313,000)  —   
Repayment of bank term loan  —     (4,000,000)
Proceeds from term loan payable  10,000,000   2,301,000 
Payments related to settlement of employee shared-based awards  (464,000)  (256,000)
Payment of deferred financing costs  (168,000)  —   
Payment on royalty liability  —     (1,000,000)
Other  (6,000)  12,000 
Net cash provided by (used in) financing activities – continuing operations  24,149,000   (2,943,000)
Net increase in cash and cash equivalents  7,476,000   760,000 
Cash and cash equivalents at beginning of period  2,409,000   1,649,000 
Cash and cash equivalents at end of period $9,885,000  $2,409,000 
         


 STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
 New Bookings
 (Unaudited)
       
   January 31, 2022
  Three Months Ended   Twelve Months Ended
Software Licenses 296,000   574,000
Professional Services                           4,352,000   5,362,000
Audit Services 255,000   890,000
Maintenance and Support 486,000   929,000
Software as a Service 2,199,000   6,129,000
Total 2021 Bookings$                         7,588,000    $ 13,884,000
       
Total 2020 Bookings $1,818,000  $7,392,000


STREAMLINE HEALTH SOLUTIONS, INC. AND SUBSIDIARIES
Reconciliation of Loss from Continuing Operations to Non-GAAP Adjusted EBITDA
(rounded to nearest thousand dollars, except share and per shares information)
          
  Three Months Ended January 31  Twelve Months Ended January 31
  2022  2021   2022  2021 
Loss from continuing operations$(4,000)$(1,590,000) $(6,917,000)$(4,799,000)
Interest expense 129,000  12,000   236,000  51,000 
Income tax expense 100,000  276,000   109,000  (1,260,000)
Depreciation 15,000  17,000   68,000  64,000 
Amortization of capitalized software development costs 418,000  534,000   1,848,000  1,662,000 
Amortization of intangible assets 560,000  121,000   1,281,000  491,000 
Amortization of other costs 111,000  117,000   449,000  359,000 
EBITDA 1,329,000  (513,000)  (2,926,000) (3,432,000)
Share-based compensation expense 557,000  400,000   2,216,000  1,403,000 
Non-cash valuation adjustments (2,268,000) (9,000)  (1,851,000) 31,000 
Loss on exit of operating lease -  -   -  105,000 
Non-Routine Costs           146,000  -   2,856,000  - 
Forgiveness of PPP loan and accrued interest -  -   (2,327,000) - 
Other Non-Recurring Chargees (64,000) -   (48,000) - 
Loss on early extinguishment of debt -  -   43,000  - 
Adjusted EBITDA$(300,000)$(122,000) $(2,037,000)$(1,893,000)
Adjusted EBITDA margin -5% -4%  -12% -17%
          
Adjusted EBITDA per Diluted Share Reconciliation         
Loss from continuing operations per common share — diluted$- $(0.05) $(0.16)$(0.16)
Adjusted EBITDA per adjusted diluted share$(0.01)$-  $(0.05)$(0.06)
          
          
Diluted weighted average shares 46,764,335  30,528,863   42,815,239  30,152,383 
Effect of dilutive securities - Stock options, Restricted stock 344,160  682,389   458,335  488,359 
Weighted average shares outstanding - Diluted 47,108,495  31,211,252   43,273,574  30,640,742 


FAQ

What were Streamline Health Solutions' fourth quarter revenues for 2021?

Streamline Health Solutions reported fourth quarter revenues of $6.0 million for 2021.

How much did SaaS revenue grow in the fourth quarter of 2021?

SaaS revenue grew by 155% in the fourth quarter of 2021 compared to the same period in 2020.

What was the net loss for Streamline Health Solutions in Q4 2021?

The net loss for Q4 2021 was $30,000.

What is the adjusted EBITDA for Streamline Health for the fourth quarter 2021?

The adjusted EBITDA for the fourth quarter of 2021 was a loss of $0.3 million.

What were the full year revenues for Streamline Health in 2021?

The full year revenues for Streamline Health in 2021 were $17.4 million, a 54% increase from 2020.

Streamline Health Solutions, Inc.

NASDAQ:STRM

STRM Rankings

STRM Latest News

STRM Stock Data

13.80M
3.48M
24.22%
20.37%
0.44%
Health Information Services
Services-computer Integrated Systems Design
Link
United States of America
ALPHARETTA